Clinical Trials · NCT07285902
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Enrollment
- 572
- Start date
- Dec 2025
- Locations
- 2 sites, China
- Primary endpoint
- Percentage change from baseline in body weight after 52 weeks of treatment